Year: 2023

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING) (Cingulate or the Company), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the quarter ended September 30, 2023, as well as a clinical and business update. Among other highlights, the Company announced data from its Phase 3 adult efficacy and safety trial, closed a $4 million public offering in September 2023 and converted of $5.8 million of debt into Cingulate equity in September 2023. “We are pleased...

Sachem Capital Reports Third Quarter 2023 Results – Produces Revenue Growth of 29.5% to $17.5 Million

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

Company to Host Webcast and Conference Call BRANFORD, Conn., Nov. 13, 2023 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) announced its financial results for the third quarter ended September 30, 2023. John Villano, CPA, Sachem Capital’s Chief Executive Officer, stated, “Once again we demonstrated our ability to grow revenue and profits during a very difficult macroeconomic backdrop. Our enhanced focus on deliberate underwriting, our conservative approach to balance sheet leverage and our experience in navigating past cycles continues to support our dividend that as of today yields over 12% on a trailing twelve month basis. Our portfolio is designed to produce steady performance in all economic conditions while protecting our capital for future opportunities.” Results of operations for quarter ended September 30,...

U.S. Energy Corp. Reports Financial and Operating Results for Third Quarter 2023

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

HOUSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in operating a portfolio of high-quality producing oil and natural gas assets, today reported financial and operating results for the three months ended September 30, 2023. THIRD QUARTER 2023 HIGHLIGHTSNet daily production of 1,652 barrels of oil equivalent per day (“Boe/d”), a 6% decrease over third quarter of 2022 Oil production of 100,071 barrels, or 66% of total production Lease Operating Expense of $4.0 million, or $26.31 per Boe, a 23% and 19% decrease, respectively, from third quarter of 2022 Adjusted EBITDA of $1.6 million during the quarterPRODUCTION UPDATE During the third quarter of 2023, the Company produced 152,013 Boe, or an average of 1,652 Boe/d, a 6% decrease compared...

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR3 16.9 months median progression free survival (mPFS) and 23.1 months median overall survival (mOS) following radiotherapy-activated (RT) NBTXR3 in topline Study 102 Phase 1 data in head and neck cancer strengthens hypotheses for pivotal NANORAY-312 trial design Promising initial anti-tumor efficacy, median overall survival (mOS) of 23 months, 92% local disease control rate (DCR), favorable safety profile and recommended dose established for NBTXR3 in locally advanced pancreatic cancer €50.9 in capital from recent financing including second equity tranche from collaboration partner extends cash runway into 2Q 2025 assuming a milestone Successful removal of the EIB cash covenant Multiple clinical readouts...

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome ELX-02 improved podocyte foot process effacement in all three treated patients by an average of 60% based on blinded biopsy analysis by NIPOKA GmbH Clinical data from Phase 2 study of ELX-02 for Alport Syndrome included in presentations at the American Society of Nephrology (ASN) Kidney Week 2023 Significant progress toward completion of a strategic partnership for ZKN-013 WATERTOWN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (OTC: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended September 30, 2023, and provided a business...

Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

– IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 – – Established new strategic collaboration with Celest Therapeutics for clinical development of SENTI-301A to treat liver cancer in China – – Cash and receivables from GeneFab transaction expected to fund operations into Q4 2024 – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2023. “The third quarter was highly productive for Senti as we continued advancing SENTI-202 towards IND clearance and further developed our platform technology,” said Timothy Lu, MD, PhD, Chief Executive...

eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Written by Customer Service on November 13, 2023. Posted in Earnings Releases And Operating Results.

Management intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium (SABCS) Topline results from Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) now anticipated in first quarter of 2024 Collaboration initiated with Northwestern University on investigator-initiated Phase 1 dose escalation trial with tomivosertib in patients with Acute Myeloid Leukemia (AML) SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate...

Core Molding Technologies Presenting at the 15th Annual Southwest IDEAS Investor Conference on November 16th in Dallas, TX

Written by Customer Service on November 13, 2023. Posted in Public Companies.

COLUMBUS, Ohio, Nov. 13, 2023 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today announced that the Company will present at the Southwest IDEAS Investor Conference at 10:05 am CT on November 16, 2023, at The Statler Dallas, and management will also be available for 1×1 meetings that day. The presentation will be webcast and may be accessed through the conference host’s main website: https://www.threepartadvisors.com/southwest and in the investor relations section of the company’s website: https://coremt.com/investor-relations/events-presentations/. About...

MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights

Written by Customer Service on November 13, 2023. Posted in Public Companies.

NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONNOVEMBER 13, 2023, 4:00 PM ET / 22:00 CET MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights IRVINE, CA, and HERSTAL, BELGIUM – November 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announces that it completed the share consolidation with respect to all its outstanding shares by means of a 1-for-10 reverse stock split (the “Share Consolidation”), the details of which were announced by press release on November 6, 2023. After close of trading on the regulated market Euronext Brussels, all 272,880,936 Company’s shares (ISIN BE0003844611) were consolidated into a new and reduced number...

HII Celebrates National Apprenticeship Week

Written by Customer Service on November 13, 2023. Posted in Public Companies.

National Apprenticeship Week 2023HII is celebrating National Apprenticeship Week. Apprenticeships are offered at each of HII’s three business divisions, including Newport News Shipbuilding.NEWPORT NEWS, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) — HII (NYSE: HII), America’s largest military shipbuilder and provider of all-domain defense solutions, is celebrating National Apprenticeship Week. Recognized by the U.S. Department of Labor, National Apprenticeship Week this year runs Nov. 13-19. It is an opportunity to highlight the success and value of apprenticeships in supporting economic growth and access to high-quality jobs. Apprenticeships are offered at each of HII’s three business divisions: Ingalls Shipbuilding, Mission Technologies and Newport News Shipbuilding. “Apprenticeship programs are the foundation in our workforce...

Year: 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals